ArriVent BioPharma, Inc. (AVBP) is an innovative biopharmaceutical company committed to advancing groundbreaking therapies for critical unmet needs in oncology and autoimmune diseases. Leveraging proprietary technologies and a robust scientific foundation, ArriVent is focused on delivering improved patient outcomes through its promising pipeline. With strategic positioning in high-growth sectors of the biopharma industry, the company represents an attractive investment opportunity for institutional investors seeking to capitalize on transformative healthcare advancements with the potential for significant market impact.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -53.20% |
| Return on Assets | -33.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $7.59 |
| Price-to-Book | 4.17 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $49.31M |
| Float | $32.11M |
| % Insiders | 1.54% |
| % Institutions | 98.68% |
Volatility is currently expanding
The Firmonertinib readout moving to H2 2026 may signal slower event accumulation and longer progression-free survival. Firmonertinib remains the core value driver, with our base case assuming meaningful penetration across EGFR exon 20 insertion and PACC populations. Pipeline optionality is expanding, with ARR-217 entering Phase 1 and ARR-002 approaching first-patient dosing.
NEWTOWN SQUARE, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent Company progress.
NEWTOWN SQUARE, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the first quarter ended March 31, 2026, and highlighted recent Company progress.
Does ArriVent BioPharma, Inc. (AVBP) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here is how ArriVent BioPharma, Inc. (AVBP) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AVBP and any ticker you trade — then tracks every position and per-strategy win rate.
